VMD Sciences spotlights managed access for canine cancer care

CURRENT FULL VERSION: VMD Sciences is using a single canine oncology case to make a broader point about access. In a January 30, 2026 press release, the company said it supported Dr. Seth Glasser, DVM, DipACVIM (Oncology), at Garden State Veterinary Specialists in importing an EMA-approved tyrosine kinase inhibitor for Jetta, an 8-year-old mixed-breed dog with metastatic mast cell cancer after standard available treatments had failed. According to the company, the drug was not commercially available in the U.S., and the import required regulatory documentation, customs clearance, and secondary FDA inspection support. (static1.squarespace.com)

The backdrop is a veterinary oncology market that has more targeted options than it did a decade ago, but still leaves gaps for difficult mast cell tumor cases. Mast cell tumors are among the most common skin tumors in dogs, and metastatic disease can be especially challenging once surgery or other first-line approaches are no longer sufficient. They are also notoriously variable at presentation: some are indolent and localized, while others are aggressive and metastatic, and they can look like ordinary skin masses until sampled. In the U.S., oncologists have access to approved or licensed products such as toceranib phosphate and, through specialists, gilvetmab, while Europe also has access to masitinib for certain canine mast cell tumor indications. (acvs.org; vetcandyradio.com)

That diagnostic uncertainty is one reason newer testing tools are drawing attention. In January 2026, IDEXX said it plans to expand its Cancer Dx Panel to include canine mast cell tumor detection beginning in mid-2026, without changing sample requirements or the typical two- to three-day turnaround time. The company also said it is adding mast cell tumor fine needle aspirate cytology to the inVue Dx Cellular Analyzer, allowing slide-free in-clinic assessment during the patient visit, with optional remote review by an IDEXX pathologist when needed. If those tools perform as advertised, they could help practices move faster from “skin mass” to a more informed diagnostic and treatment conversation. (vetcandyradio.com)

VMD Sciences framed the case as an example of its Managed Access Program, which it says uses country-specific regulatory pathways to help veterinarians obtain hard-to-access drugs and devices for eligible animals. In Jetta’s case, the company said Dr. Glasser submitted medical records, a prescription, and clinical justification, after which VMD Sciences helped manage the importation workflow. In the release, Glasser said the process took “maybe 10 minutes” of his time and that the drug arrived within days, suggesting the company is positioning regulatory support, rather than drug discovery, as its core value proposition. (vmdsciences.com)

The release does not name the imported product, but the description strongly suggests an EMA-authorized canine mast cell tumor TKI, most plausibly masitinib, which has long been available in Europe for non-resectable grade 2 or 3 mast cell tumors with confirmed mutated c-KIT. That said, VMD Sciences did not identify the molecule, indication details, mutation status, dose, or early clinical response, so any conclusion about the exact drug should be treated as an inference rather than a confirmed fact. (static1.squarespace.com)

Access to the anticancer drug is only part of the real-world oncology picture. Supportive care often determines whether a dog can stay on treatment, and chemotherapy-induced diarrhea remains a common reason protocols become harder to maintain. In December 2025, the FDA renewed conditional approval of crofelemer delayed-release tablets (Canalevia-CA1) for chemotherapy-induced diarrhea in dogs through December 21, 2026. Jaguar Health has said the product’s full effectiveness study is underway, making this the fifth and final allowable year of conditional approval for that indication. For clinicians, the renewal preserves an indication-specific option aimed at reducing intestinal chloride secretion and fluid loss without slowing gut transit, potentially helping maintain hydration, comfort, and nutritional status during cancer treatment. (vetcandyradio.com)

Industry reaction appears limited so far, with most coverage tracing back to the company’s own announcement. Still, the case fits a wider push by VMD Sciences to normalize veterinary expanded access and managed access models that are already familiar in human medicine. The company launched broader expanded access messaging in 2024, describing these programs as a way to provide eligible animals with therapies unavailable through standard channels. (businesswire.com)

Why it matters: For veterinary professionals, the most important takeaway isn’t one dog or one imported drug. It’s the signal that regulatory navigation may become a more visible part of specialty oncology practice, particularly for pet parents seeking additional options after standard protocols fail. At the same time, the mast cell tumor workflow is evolving on both ends: earlier detection may improve as blood-based screening and in-clinic cytology tools expand, while supportive-care options like Canalevia-CA1 may help some patients better tolerate chemotherapy when it is used. If these pathways prove workable, they could give oncologists another tool for highly selected patients, but they also raise practical questions around evidence standards, informed consent, cost, supply continuity, adverse-event monitoring, and how to counsel pet parents when a therapy is approved abroad but not in the U.S. (static1.squarespace.com; vetcandyradio.com; vetcandyradio.com)

There’s also a cautionary note. This announcement is a case report in press-release form, not a clinical study, and it does not provide outcome data beyond treatment initiation. For clinicians, that means the operational success is real, but the clinical significance remains unproven from the information released publicly. The value today is in the access model, not in any demonstrated new efficacy signal. (static1.squarespace.com)

What to watch: The next markers will be whether VMD Sciences publishes additional managed access oncology cases, whether specialty hospitals adopt the pathway more broadly, whether IDEXX’s planned mast cell tumor additions gain meaningful uptake in practice, and whether any imported therapies eventually move toward formal U.S. veterinary commercialization or structured evidence generation. (businesswire.com)